Aytu BioPharma, Inc.

AYTU

US0547548588

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.904 ^USD	+2.26%		+4.10%	+2.26%

Feb. 14	Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024
Feb. 14	Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M	MT

Neos Therapeutics, Inc. announced that it has received $5 million in funding from Aytu BioScience, Inc.

February 07, 2021

On February 8, 2021, Neos Therapeutics, Inc. (NasdaqGM:NEOS) closed the transaction. The transaction got approved by the Nasdaq Stock Market.

Latest news about Aytu BioPharma, Inc.

Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024	Feb. 14
Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M	Feb. 14	MT
Aytu BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 14	CI
Transcript : Aytu BioPharma, Inc., Q1 2024 Earnings Call, Nov 14, 2023	Nov. 14
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q1 Revenue $22.1M, vs. Street Est of $27.7M	Nov. 14	MT
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
Aytu BioPharma Gets FDA Approval to Transfer Production of Cotempla to Third Party	23-10-26	MT
Aytu BioPharma, Inc. Announces Approval of the Cotempla XR-ODT Manufacturing Site Transfer Prior Approval Supplement	23-10-26	CI
Aytu BioPharma, Inc. Announces Resignation of Christopher Brooke as Chief Operating Officer	23-10-06	CI
Earnings Flash (AYTU) AYTU BIOPHARMA Posts Q4 Revenue $30.7M, vs. Street Est of $27.7M	23-09-27	MT
Aytu BioPharma, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	23-09-27	CI
Aytu BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-27	CI
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields	23-09-27	DJ
Maxim Starts Aytu BioPharma at Buy With $5 Price Target	23-08-09	MT
Aytu BioPharma, Inc. Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-OT(R) in Israel and the Arab Authority	23-07-31	CI
Aytu BioPharma, Inc. Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement	23-07-10	CI
Aytu BioPharma, Inc. Appoints Abhinav "Abi" Jain to the Board of Directors	23-06-09	CI
Transcript : Aytu BioPharma, Inc., Q3 2023 Earnings Call, May 11, 2023	23-05-11
Aytu BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-11	CI
Wall Street Set to Open Slightly Lower Ahead of Fed Meeting, US Factory Order Data	23-05-02	MT
Aytu BioPharma Subleases A Portion of Its Manufacturing Facility	23-05-01	CI
Aytu BioPharma Receives FDA Approval to Transfer Manufacturing Site of Adzenys XR-ODT	23-04-27	MT
Aytu Biopharma, Inc. Announces Successfully Completion of Cotempla XR-ODT Bioequivalence Study	23-04-27	CI
Aytu BioPharma, Inc. Receives U.S. Food & Drug Administration Approval of the Adzenys XR-ODT Manufacturing of Adzenys to the Third-Party Manufacturer	23-04-27	CI
Transcript : Aytu BioPharma, Inc., Q2 2023 Earnings Call, Feb 21, 2023	23-02-21

Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Companyâs Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Companyâs prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Aytu BioPharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.904 USD

Average target price

8 USD

Spread / Average Target

+175.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AYTU BIOPHARMA, INC.	+2.26%	16.17M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Aytu BioPharma, Inc.

Equities

AYTU

US0547548588

Pharmaceuticals

Neos Therapeutics, Inc. announced that it has received $5 million in funding from Aytu BioScience, Inc.

Latest news about Aytu BioPharma, Inc.

Chart Aytu BioPharma, Inc.

Company Profile

Income Statement Evolution

Ratings for Aytu BioPharma, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals